Not a traditional drug phase: testing CD34 Positive Stem Cell Infusion for Blood And Marrow Transplantation
Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
Official registry: https://clinicaltrials.gov/study/NCT02438904 · M.D. Anderson Cancer Center · enrollment listed as 200
What this phase means
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are CD34 Positive Stem Cell Infusion, or Miltenyi device. The registry lists allocation as na. Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
They plan to enroll about 200 people at Houston. Taking part typically means an infusion or injection of a biologic, using or being fitted with a device plus check-ins.
Official title (unrewritten)
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
Interventions: CD34 Positive Stem Cell Infusion, Miltenyi device
Primary outcome (registry wording): Increased Graft Function after Stem Cell Transplantation (SCT)
Who it is for (from inclusion criteria)
- 1\) Patients who have poor or no graft function post stem cell transplantation
Who the registry excludes
- People the protocol lists as excluded — the study team must confirm.
Public study contact (from the registry)
Elizabeth Shpall, MD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- University of Texas MD Anderson Cancer Center — Houston, Texas (recruiting)
FAQ about this NCT record
Is NCT02438904 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT02438904?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT02438904?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary